Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 1
2019 1
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Structure-Based Design of Selective Noncovalent CDK12 Inhibitors.
Johannes JW, Denz CR, Su N, Wu A, Impastato AC, Mlynarski S, Varnes JG, Prince DB, Cidado J, Gao N, Haddrick M, Jones NH, Li S, Li X, Liu Y, Nguyen TB, O'Connell N, Rivers E, Robbins DW, Tomlinson R, Yao T, Zhu X, Ferguson AD, Lamb ML, Manchester JI, Guichard S. Johannes JW, et al. Among authors: haddrick m. ChemMedChem. 2018 Feb 6;13(3):231-235. doi: 10.1002/cmdc.201700695. Epub 2018 Jan 26. ChemMedChem. 2018. PMID: 29266803
Organ-on-a-chip technology: turning its potential for clinical benefit into reality.
Haddrick M, Simpson PB. Haddrick M, et al. Drug Discov Today. 2019 May;24(5):1217-1223. doi: 10.1016/j.drudis.2019.03.011. Epub 2019 Mar 14. Drug Discov Today. 2019. PMID: 30880172 Review.
Understanding Cytotoxicity and Cytostaticity in a High-Throughput Screening Collection.
Mervin LH, Cao Q, Barrett IP, Firth MA, Murray D, McWilliams L, Haddrick M, Wigglesworth M, Engkvist O, Bender A. Mervin LH, et al. Among authors: haddrick m. ACS Chem Biol. 2016 Nov 18;11(11):3007-3023. doi: 10.1021/acschembio.6b00538. Epub 2016 Sep 13. ACS Chem Biol. 2016. PMID: 27571164 Free article.
Translational Roadmap for the Organs-on-a-Chip Industry toward Broad Adoption.
Allwardt V, Ainscough AJ, Viswanathan P, Sherrod SD, McLean JA, Haddrick M, Pensabene V. Allwardt V, et al. Among authors: haddrick m. Bioengineering (Basel). 2020 Sep 16;7(3):112. doi: 10.3390/bioengineering7030112. Bioengineering (Basel). 2020. PMID: 32947816 Free PMC article. Review.
Ultrasound-triggered therapeutic microbubbles enhance the efficacy of cytotoxic drugs by increasing circulation and tumor drug accumulation and limiting bioavailability and toxicity in normal tissues.
Ingram N, McVeigh LE, Abou-Saleh RH, Maynard J, Peyman SA, McLaughlan JR, Fairclough M, Marston G, Valleley EMA, Jimenez-Macias JL, Charalambous A, Townley W, Haddrick M, Wierzbicki A, Wright A, Volpato M, Simpson PB, Treanor DE, Thomson NH, Loadman PM, Bushby RJ, Johnson BRG, Jones PF, Evans JA, Freear S, Markham AF, Evans SD, Coletta PL. Ingram N, et al. Among authors: haddrick m. Theranostics. 2020 Sep 1;10(24):10973-10992. doi: 10.7150/thno.49670. eCollection 2020. Theranostics. 2020. PMID: 33042265 Free PMC article.
Feedback